Breaking through BCL-2 inhibition in CLL

Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia

(2019) Eugen Tausch et al.   HAEMATOLOGICA

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies

(2019) Romain Guièze et al.   CANCER CELL

A feedforward relationship between active Rac1 and phosphorylated Bcl-2 is critical for sustaining Bcl-2 phosphorylation and promoting cancer progression

(2019) Stephen Jun Fei Chong et al.   CANCER LETTERS

The rise of apoptosis: targeting apoptosis in hematologic malignancies

(2018) Rebecca Valentin et al.   BLOOD

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

(2018) John F. Seymour et al.   NEW ENGLAND JOURNAL OF MEDICINE

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

(2018) Courtney D. DiNardo et al.   BLOOD

Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia

(2018) Piers Blombery et al.   Cancer Discovery

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

(2017) Matthew S. Davids et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

(2016) Andrew W. Roberts et al.   NEW ENGLAND JOURNAL OF MEDICINE